A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.
We have sought mutations in the recently identified neurofibromatosis type 2 (NF2) tumor-suppressor gene in a large panel of NF2 patients, using PCR-based SSCP and heteroduplex analysis, followed by cloning and sequencing of appropriate PCR products. Two unrelated NF2 patients were found to have identical nonsense mutations caused by a C-to-T transition in a CpG dinucleotide that is a potential mutational hot spot in the NF2 tumor-suppressor gene. Unexpectedly, the two individuals had widely different clinical phenotypes, representing the severe Wishart and mild Gardner clinical subtypes. Analysis of DNA samples from different tissues of the mildly affected patient suggests that he is a somatic mosaic for the mutation.
Bourn
D
D
Division of Human Genetics, University of Newcastle upon Tyne, United Kingdom.
Carter
S A
SA
Evans
D G
DG
Goodship
J
J
Coakham
H
H
Strachan
T
T
D000293:Adolescent; D000328:Adult; D001483:Base Sequence; D004252:DNA Mutational Analysis; D015226:Dinucleoside Phosphates / Q000235:genetics; D016515:Genes, Neurofibromatosis 2 / Q000235:genetics*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009030:Mosaicism; D016518:Neurofibromatosis 2 / Q000235:genetics* / Q000473:pathology; D009690:Nucleic Acid Conformation; D009692:Nucleic Acid Heteroduplexes; D010375:Pedigree; D010641:Phenotype; D017354:Point Mutation
D015226:Dinucleoside Phosphates; D009692:Nucleic Acid Heteroduplexes; C015772:CpG dinucleotide